{"id":1068381,"date":"2022-12-08T00:13:47","date_gmt":"2022-12-08T05:13:47","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/ngm-bio-presents-preliminary-data-from-phase-1-monotherapy-dose-escalation-trial-of-ngm707-in-patients-with-advanced-or-metastatic-solid-tumors-at\/"},"modified":"2024-08-18T11:46:32","modified_gmt":"2024-08-18T15:46:32","slug":"ngm-bio-presents-preliminary-data-from-phase-1-monotherapy-dose-escalation-trial-of-ngm707-in-patients-with-advanced-or-metastatic-solid-tumors-at","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/ngm-bio-presents-preliminary-data-from-phase-1-monotherapy-dose-escalation-trial-of-ngm707-in-patients-with-advanced-or-metastatic-solid-tumors-at.php","title":{"rendered":"NGM Bio Presents Preliminary Data from Phase 1 Monotherapy Dose Escalation Trial of NGM707 in Patients with Advanced or Metastatic Solid Tumors at&#8230;"},"content":{"rendered":"<p><![CDATA[SOUTH SAN FRANCISCO, Calif., Dec.  07, 2022  (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced the presentation of preliminary data from the Phase 1 Part 1a monotherapy dose escalation arm of the ongoing Phase 1\/2 trial of NGM707 in patients with advanced or metastatic solid tumors at the European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Annual Congress, which is taking place December 7 \u2013 9, 2022 in Geneva, Switzerland. In the poster presentation titled, \u201cFirst-in-Human Study of NGM707, an ILT2\/ILT4 Dual Antagonist Antibody in Advanced or Metastatic Solid Tumors: Preliminary Monotherapy Dose Escalation Data\u201d (#174P), NGM707 was generally well tolerated across all dose cohorts and demonstrated promising early signals of anti-tumor activity. Of 24 response-evaluable patients in the Part 1a arm, best overall responses as of November 23, 2022 are partial response in one patient, stable disease in six patients and non-complete response\/non-progressive disease in one patient. Six patients had reduced target lesion size including a maximum decrease in one patient of 70%. A copy of the presentation presented at the ESMO I-O Annual Congress is available on NGM Bio\u2019s website at\u00a0https:\/\/www.ngmbio.com\/discovery-engine\/publications\/.]]><\/p>\n<p>See the article here:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/news-release\/2022\/12\/07\/2569796\/0\/en\/NGM-Bio-Presents-Preliminary-Data-from-Phase-1-Monotherapy-Dose-Escalation-Trial-of-NGM707-in-Patients-with-Advanced-or-Metastatic-Solid-Tumors-at-2022-ESMO-IO-Annual-Meeting.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"NGM Bio Presents Preliminary Data from Phase 1 Monotherapy Dose Escalation Trial of NGM707 in Patients with Advanced or Metastatic Solid Tumors at...\">NGM Bio Presents Preliminary Data from Phase 1 Monotherapy Dose Escalation Trial of NGM707 in Patients with Advanced or Metastatic Solid Tumors at...<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>See the article here: NGM Bio Presents Preliminary Data from Phase 1 Monotherapy Dose Escalation Trial of NGM707 in Patients with Advanced or Metastatic Solid Tumors at... <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/ngm-bio-presents-preliminary-data-from-phase-1-monotherapy-dose-escalation-trial-of-ngm707-in-patients-with-advanced-or-metastatic-solid-tumors-at.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-1068381","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068381"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1068381"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068381\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1068381"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1068381"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1068381"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}